Streetbeat News

CMPS

COMPASS Pathways plc

Industry

Medical - Care Facilities

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Open

5.15

Mkt cap

345M

Volume

3.6M

High

6.04

P/E Ratio

-2.31

52-wk high

12.75

Low

4.97

Div yield

N/A

52-wk low

4.05

HC Wainwright & Co. has maintained a Buy rating on Compass Pathways (NASDAQ:CMPS) but has lowered the price target from $120 to $60.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 8:26 pm

Maxim Group analyst Jason McCarthy maintains a Buy rating on Compass Pathways (NASDAQ:CMPS) but lowers the price target from $22 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 6:13 pm

RBC Capital analyst Leonid Timashev maintains an Outperform rating on Compass Pathways (NASDAQ:CMPS) but lowers the price target from $23 to $18.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 4:44 pm

U.S. stocks fell with the Nasdaq down 500 points. Uber shares dropped over 10% despite beating earnings expectations. Root, Alphatec, and Lemonade saw significant gains after positive earnings reports, while Matinas BioPharma, Aurora Innovation, and COMPASS Pathways experienced sharp declines.

Portfolio Pulse from Avi Kapoor

October 31, 2024 | 6:43 pm

Compass Pathways (CMPS) faces delays in its Phase 3 psilocybin trials, leading to a 30% workforce reduction to conserve cash. The company aims to focus on its COMP360 program for treatment-resistant depression, with trial data now expected in 2025 and 2026. Shares fell 23.02% following the announcement.

Portfolio Pulse from Juan Spínelli

October 31, 2024 | 6:30 pm

The article highlights significant intraday movements in healthcare stocks, with Biofrontera, Autonomix Medical, Anavex Life Sciences, Aerovate Therapeutics, MiMedx Group, and Exicure seeing gains, while Matinas BioPharma, Anika Therapeutics, Psyence Biomedical, CalciMedica, Compass Pathways, and Vaccinex experienced losses.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 4:34 pm

U.S. stocks traded lower with significant movements in Meta Platforms, Root, Alphatec Holdings, Matinas BioPharma, Aurora Innovation, and COMPASS Pathways. Meta's shares fell after Q3 results, while Root and Alphatec surged on positive earnings. Matinas, Aurora, and COMPASS Pathways saw declines due to negative news.

Portfolio Pulse from Avi Kapoor

October 31, 2024 | 4:04 pm

Several major stocks, including Estée Lauder, Robinhood, and eBay, are experiencing significant declines in pre-market trading. Estée Lauder's shares fell 17% after withdrawing FY25 guidance due to uncertainties in China and leadership changes. Other companies like Aurora Innovation, Roku, and Monolithic Power Systems also reported losses following earnings results.

Portfolio Pulse from Avi Kapoor

October 31, 2024 | 1:18 pm

Compass Pathways shares declined after the company delayed the topline data readout for its COMP005 Phase 3 trial to Q2 2025 and announced that COMP006 data will be available after the 26-week time point.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 1:10 pm

The article highlights significant pre-market movements in healthcare stocks on Thursday. Notable gainers include Autonomix Medical, Tenon Medical, and Aerovate Therapeutics, while Matinas BioPharma and Equillium are among the biggest losers. Several companies reported Q3 earnings, impacting their stock prices.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 12:10 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.